Quote | Opthea Limited (NASDAQ:OPT)
Last: | $3.41 |
---|---|
Change Percent: | 4.19% |
Open: | $3.43 |
Close: | $3.41 |
High: | $3.4899 |
Low: | $3.38 |
Volume: | 7,762 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Opthea Limited (NASDAQ:OPT)
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, includ...
2024-04-25 11:15:04 ET Oppenheimer analyst issues OUTPERFORM recommendation for OPT on April 25, 2024 09:26AM ET. The previous analyst recommendation was Outperform. OPT was trading at $3.43 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Message Board Posts | Opthea Limited (NASDAQ:OPT)
Subject | By | Source | When |
---|---|---|---|
$OPT: Sudden popping to $14.............. | makinezmoney | investorshub | 06/16/2021 2:41:09 PM |
News, Short Squeeze, Breakout and More Instantly...
Opthea Limited Company Name:
OPT Stock Symbol:
NASDAQ Market:
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biophar...
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, includ...
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage bioph...